MYOVANT SCIENCES LTD.

Inactive Instrument

Analyst Reco. Myovant Sciences Ltd.

Equities

MYOV

BMG637AM1024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evercore ISI Downgrades Myovant Sciences to In Line From Outperform With $27 Price Target	22-10-26	MT
SVB Securities Downgrades Myovant Sciences to Market Perform From Outperform, Adjusts Price Target to $27 From $23	22-10-25	MT
Baird Downgrades Myovant Sciences to Neutral From Outperform, Raises Price Target to $27 From $20	22-10-24	MT
SVB Securities Upgrades Myovant Sciences to Outperform From Market Perform, Adjusts Price Target to $23 From $12	22-08-09	MT
Goldman Sachs Raises Myovant Sciences Price Target to $10 From $9, Maintains Neutral Rating	22-07-28	MT
Baird Adjusts Myovant Sciences' Price Target to $20 From $30, Keeps Outperform Rating	22-04-13	MT
SVB Leerink Adjusts Myovant Sciences' Price Target to $12 From $19, Keeps Market Perform Rating	22-04-13	MT
SVB Leerink Adjusts Myovant Sciences Price Target to $19 From $21, Maintains Market Perform Rating	22-02-16	MT
SVB Leerink Adjusts Myovant Sciences Price Target to $21 From $23, Maintains Market Perform Rating	22-01-05	MT
MYOVANT SCIENCES : SVB Leerink Starts Myovant Sciences at Market Perform with $24 Price Target	21-09-09	MT
MYOVANT SCIENCES : Citigroup Adjusts Price Target on Myovant Sciences to $24 From $30, Maintains Neutral Rating	21-05-13	MT
MYOVANT SCIENCES : SVB Leerink Downgrades Myovant Sciences to Market Perform From Outperform; Price Target is $28	21-01-08	MT
MYOVANT SCIENCES : Goldman Sachs Downgrades Myovant Sciences to Neutral from Buy, Sets $30 Price Target	21-01-06	MT
Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids	20-02-10	CI
Myovant Sciences Announces 97% Response Rate in Positive Phase 3 Hero Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer	19-11-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer